

Appendix D

Pharmacogenomics in the Community: A Study of Plavix®
Plavix® (clopidogrel) Research Study Result

Date: Click here to enter text. Pages (including cover):
To: Click here to enter text. From:
Fax: Click here to enter text. Fax: 919-537-4011
Phone: Click here to enter text. Phone: 919-918-7595
Re: Click here to enter text.

APPROVED - IRB, UNC-CH
SEP 27 2011

Dear Dr. Click here to enter text. ,

I received the report on Patient Name (DOB) regarding their Plavix® CYP2C19 genotype test result. Your patient was enrolled in a study approved by UNC IRB (Study number 10.1558), and this patient's DNA was tested for variabilities in the alleles of the CYP2C19 metabolizing enzyme, the enzyme most responsible for converting Plavix® to its active form. The patient has wild-type alleles (CYP2C19 *1/*1) of the CYP2C19 metabolizing enzyme, suggesting no genetically-predicted alteration in metabolism of Plavix®. Based on the genotype results, current literature supports maintaining clopidogrel 75mg once daily.

The laboratory report is included in this fax, so you can review information on the testing and interpretation of that result.

I will contact the patient within a week to set up an appointment to counsel the patient regarding their genotype test result. Please don't hesitate to contact me with your questions or concerns regarding how we can best optimize the quality of patient care.

Thank you for your time,

Clinical Pharmacist
Kerr Health

Please sign below and provide the ICD-9 diagnosis code associated with clopidogrel treatment

Prescriber Signature _____ ICD-9 code _____



Pharmacogenomics in the Community: A Study of Plavix®
Plavix® (clopidogrel) Research Study Result

Date: Click here to enter text.

Pages (including cover): 2

To: Click here to enter text.

From:

APPROVED - IRB UNC-CH

Fax: Click here to enter text.

Fax: 919-537-4011

SEP 27 2011

Phone: Click here to enter text.

Phone: 919-918-7595

Re: Click here to enter text.

Dear Dr. Click here to enter text. ,

I received the report on **Patient Name (DOB)** regarding their Plavix® CYP2C19 genotype test result. Your patient was enrolled in a study approved by UNC IRB (Study number 10.1558), and this patient's DNA was tested for variabilities in the alleles of the CYP2C19 metabolizing enzyme, the enzyme most responsible for converting Plavix® to its active form. The patient has non-wild-type alleles of the CYP2C19 metabolizing enzyme, suggesting the patient may have altered metabolism of clopidogrel. Specifically, the patient's genotype is [Click here to enter text.](#) The laboratory report is included in this fax, so you can review information on the testing and interpretation of that result. Based on the results, current literature supports a change in therapy.

Please consider the following recommendation:

[Insert Recommendation here based on indication for Plavix®, patient-specific data, and pharmacogenomic test result.]

Prescriber Signature _____ ICD-9 code _____

Continue current therapy with no change. Instruct patient to follow up with prescriber (circle one) **as scheduled** or in -
_____.

Prescriber Signature _____ ICD-9 code _____

****Please sign and provide the ICD-9 diagnosis code associated with clopidogrel treatment****

Please indicate your preference for treatment by signing and returning via **fax to 919-537-4011**. Upon receipt of your response, I will counsel the patient regarding their pharmacogenomic test result and your intention for treatment. Please don't hesitate to contact me with your questions or concerns regarding how we can best optimize the quality of patient care.

Thank you for your time,

Clinical Pharmacist

Kerr Health